{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:29:30Z","timestamp":1781706570736,"version":"3.54.5"},"reference-count":16,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/bmj.com\/coronavirus\/usage"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2021,9,2]]},"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:p>This study aimed to determine antibody responses against SARS-CoV-2 spike (S) after both BioNTech\u2013Pfizer Comirnaty vaccine doses and study the correlation with self-perceived adverse reactions. Antibodies determination with Elecsys anti-SARS-CoV-2 S assay was performed a day prior to or just before administration of the second dose and 8\u201313\u2009days after the second dose. Participants selected from a predefined list of the experienced local (injection site reactions) and\/or systemic (fatigue, headache, myalgia, arthralgia, chills and fever) post-vaccination adverse reactions. An average 100-fold increase in antibody titre in naive vaccinees was observed between the two time points (median 67\u2009U\/mL vs 2841\u2009U\/mL, p&lt;0.001). Participants aged below 50 had higher antibody titres (median 99 U\/mL vs 26\u2009U\/mL, p=0.003 after the first dose; median 3617 U\/mL vs 2556\u2009U\/mL, p=0.026 after the second dose). All reported adverse reactions were mild-to-moderate, with more participants declaring systemic reactions after the second dose (p=0.001), without a clear correlation with antibody titre.<\/jats:p>","DOI":"10.1136\/jclinpath-2021-207572","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T13:25:20Z","timestamp":1631712320000},"page":"782-786","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Antibody response and self-reported adverse reactions following vaccination with Comirnaty: a pilot study from a Croatian university hospital"],"prefix":"10.1136","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0854-4526","authenticated-orcid":false,"given":"Ivana","family":"Lapi\u0107","sequence":"first","affiliation":[{"name":"Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dunja","family":"Rogi\u0107","sequence":"additional","affiliation":[{"name":"Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragana","family":"\u0160egulja","sequence":"additional","affiliation":[{"name":"Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ljiljana","family":"Zaninovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,9,15]]},"reference":[{"key":"2025120520232454000_75.11.782.1","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1515\/cclm-2021-0038","article-title":"Kinetics and biological characteristics of humoral response developing after SARS-CoV-2 infection: implications for vaccination","volume":"59","author":"Lippi","year":"2021","journal-title":"Clin Chem Lab Med"},{"key":"2025120520232454000_75.11.782.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"},{"key":"2025120520232454000_75.11.782.3","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1177\/0192623320959090","article-title":"Review of current vaccine development strategies to prevent coronavirus disease 2019 (COVID-19)","volume":"48","author":"Bennet","year":"2020","journal-title":"Toxicol Pathol"},{"key":"2025120520232454000_75.11.782.4","unstructured":"Comirnaty, INN-COVID-19 mRNA vaccine (nucleoside-modified) . Annex I \u2013 summary of product characteristics. Available: https:\/\/ema.europa.eu [Accessed 7 Mar 2021]."},{"key":"2025120520232454000_75.11.782.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMC2036242"},{"key":"2025120520232454000_75.11.782.6","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and T\n                  H\n               1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"2025120520232454000_75.11.782.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2639-4"},{"key":"2025120520232454000_75.11.782.8","doi-asserted-by":"crossref","first-page":"832","DOI":"10.3390\/diagnostics11050832","article-title":"Anti-SARS-CoV-2 receptor-binding domain total antibodies response in seropositive and seronegative healthcare workers undergoing COVID-19 mRNA BNT162b2 vaccination","volume":"11","author":"Salvagno","year":"2021","journal-title":"Diagnostics"},{"key":"2025120520232454000_75.11.782.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2021.04.006"},{"key":"2025120520232454000_75.11.782.10","doi-asserted-by":"crossref","first-page":"1351.e5","DOI":"10.1016\/j.cmi.2021.05.004","article-title":"Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)","volume":"27","author":"Favresse","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2025120520232454000_75.11.782.11","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1002\/jmv.26899","article-title":"Antibody response patterns in COVID-19 patients with different levels of disease severity in Japan","volume":"93","author":"Imai","year":"2021","journal-title":"J Med Virol"},{"key":"2025120520232454000_75.11.782.12","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(21)00502-X","article-title":"Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine","volume":"397","author":"Prendecki","year":"2021","journal-title":"Lancet"},{"key":"2025120520232454000_75.11.782.13","article-title":"Age-Dependent immune response to the Biontech\/Pfizer BNT162b2 COVID-19 vaccination","author":"M\u00fcller","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025120520232454000_75.11.782.14","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abe0240"},{"key":"2025120520232454000_75.11.782.15","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2021.3341"},{"key":"2025120520232454000_75.11.782.16","doi-asserted-by":"crossref","unstructured":"Krammer F , Srivastava K . The Paris team, et al. robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine. medRxiv.doi:10.1101\/2021.01.29.21250653","DOI":"10.1101\/2021.01.29.21250653"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2021-207572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:23:33Z","timestamp":1764995013000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2021-207572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,15]]},"references-count":16,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,10,18]]},"published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1136\/jclinpath-2021-207572"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2021-207572","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,15]]}}}